Lina Gugucheva, NewAmsterdam Pharma CBO
Pharma group bets up to $1B-plus on the PhIII resurrection of a once dead-and-buried LDL drug
Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
